Lansforsakringar Fondforvaltning AB publ Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

Lansforsakringar Fondforvaltning AB publ acquired a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 107,880 shares of the company's stock, valued at approximately $4,486,000.

Several other large investors have also added to or reduced their stakes in MRNA. FMR LLC raised its position in shares of Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares during the last quarter. Theleme Partners LLP lifted its stake in Moderna by 1.0% in the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock worth $303,819,000 after acquiring an additional 72,028 shares during the period. Geode Capital Management LLC lifted its stake in Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after acquiring an additional 171,774 shares during the period. Invesco Ltd. lifted its position in shares of Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after buying an additional 979,858 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Moderna during the fourth quarter valued at about $163,833,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Down 1.4%

Shares of NASDAQ:MRNA traded down $0.37 during trading on Friday, reaching $26.56. 30,650,266 shares of the company traded hands, compared to its average volume of 8,163,834. The firm has a fifty day simple moving average of $26.55 and a 200 day simple moving average of $34.03. The firm has a market cap of $10.27 billion, a P/E ratio of -2.86 and a beta of 1.99. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $158.82.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company's revenue for the quarter was down 35.3% on a year-over-year basis. During the same quarter last year, the business posted ($3.07) EPS. As a group, research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Morgan Stanley cut their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Citigroup initiated coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price target on the stock. Barclays dropped their target price on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. William Blair restated a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. Finally, JPMorgan Chase & Co. dropped their target price on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a report on Thursday, May 22nd. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $53.58.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.